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Background
Artemisinin resistant P. falciparum malaria has emerged
in Western Cambodia and now has been observed in
Thailand, Vietnam and Myanmar and Lao. In addition,
there is a recent report of a Vietnamese patient, apparently
infected with P. falciparum in Angola, who was unrespon-
sive to artemisinin treatment. This makes it even more
urgent to have baseline information on early parasite
response to ACTs in African patients, the first step in
establishing surveillance for this important phenotype.
Materials and methods
Individual patient data from efficacy trials conducted
between 1999 and 2012 were shared with the Worldwide
Antimalarial Resistance Network (WWARN) and pooled
analyses conducted using standardized methodology. Fac-
tors affecting early parasitological response to treatment
were investigated using logistic regression with study sites
fitted as a random effect.
Results
Data from 85 studies (N = 29,664) conducted in 27 coun-
tries with Artemether-lumefantrine (AL, n = 13,664),
Artesunate-amodia-quine-fixed dose combination
(ASAQ-F; n = 4,097), Artesunate-amodiaquine-co-blister
combination (ASAQ-C; n = 2,505), Artesunate-amodia-
quine-loose combination (ASAQ-L; n = 4,096), and Di
hydro artemisinin-piperaquine (DP; n = 4,492) were
included. With all drugs tested, high baseline parasite
density and fever were both independent predictors of
persistent parasitemia on days 1, 2 and 3. Adjusted for
these variables, patients from 1 to 5 years and from 5 to
12 years in areas of low/moderate transmission were at a
2-fold and 4-fold risk of persistent parasitemia on day 3
compared to patients of the same age-group in high
transmission settings. Treatment with AL was associated
with a higher risk of persistent parasitemia on day 1
(AOR = 1.57 [95% CI: 1.38-1.78], P < 0.001) and day 2
(AOR = 1.21 [95% CI: 1.01-1.45], P = 0.043) compared to
treatment with DP. Treatment with ASAQ-L was also
associated with a higher risk of persistent parasitemia on
day 2 (AOR = 1.59 [95% CI: 1.16-2.18], P = 0.004) and
day 3 (AOR = 2.62 [95% CI: 1.24-5.53], P = 0.012) com-
pared to treatment with DP.
Conclusions
These results show no evidence of slow parasite clear-
ance in these African studies. The greatest risk of slow
clearance was observed in patients from areas of low/
moderate transmission. The threshold for suspected
diminished parasite susceptibility to artemisinins on day
3 was estimated to be 5%, much lower than the cur-
rently used World Health Organisation threshold of
10%. However, there are clear gaps in surveillance and
any sites exceeding the day 3 parasite positivity rate of
5% should be further investigated.
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